Can Vilazodone Offer New Hope for Parkinson's-Related Dyskinesia?
A recent study explores the potential of Vilazodone, a unique antidepressant, to alleviate L-DOPA-induced dyskinesia in Parkinson's disease, offering a promising avenue for improving treatment outcomes.